{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:12:30Z","timestamp":1771373550043,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00213-024-06658-x","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:03:49Z","timestamp":1722956629000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia:\u00a0A\u00a01-year retrospective cohort study"],"prefix":"10.1007","volume":"242","author":[{"given":"Masaru","family":"Tsukahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-4786","authenticated-orcid":false,"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"6658_CR1","doi-asserted-by":"publisher","unstructured":"Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 8:CD008016. https:\/\/doi.org\/10.1002\/14651858.CD008016.pub3","DOI":"10.1002\/14651858.CD008016.pub3"},{"key":"6658_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euroneuro.2023.07.007","volume":"75","author":"SKW Chan","year":"2023","unstructured":"Chan SKW, Suen YN, Yan WC, Lam C, Chui E, Hui CLM, Chang WC, Lee EHM, Chen EYH, Honer WG, Takeuchi H (2023) Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. Eur Neuropsychopharmacol 75:67\u201379. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.007","journal-title":"Eur Neuropsychopharmacol"},{"key":"6658_CR3","unstructured":"FDA (2020) CLOZARIL\u00ae Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/019758s095lbl.pdf. Accessed 19 Jun 2024"},{"key":"6658_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garc\u00eda","year":"2016","unstructured":"Garc\u00eda S, Mart\u00ednez-Cengotitabengoa M, L\u00f3pez-Zurbano S, Zorrilla I, L\u00f3pez P, Vieta E, Gonz\u00e1lez-Pinto A (2016) Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:355\u2013371. https:\/\/doi.org\/10.1097\/JCP.0000000000000523","journal-title":"J Clin Psychopharmacol"},{"key":"6658_CR5","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology. U.S. Department of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, national institute of mental health, psychopharmacology research branch, division of extramural research programs, pp 218\u2013222"},{"key":"6658_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"6658_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654\u2013659. https:\/\/doi.org\/10.1192\/bjp.166.5.654","journal-title":"Br J Psychiatry"},{"key":"6658_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"6658_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796. https:\/\/doi.org\/10.1001\/archpsyc.1988.01800330013001","journal-title":"Arch Gen Psychiatry"},{"key":"6658_CR10","doi-asserted-by":"publisher","unstructured":"Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer J-P, Marder S, Olfson M, Potkin SG, Correll CU (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 80:18com12123. https:\/\/doi.org\/10.4088\/JCP.18com12123","DOI":"10.4088\/JCP.18com12123"},{"key":"6658_CR11","doi-asserted-by":"publisher","unstructured":"Kikuchi Y, Shimomura Y, Suzuki T, Uchida H, Mimura M, Takeuchi H (2021) Single versus multiple daily dosing regimens of psychotropic drugs for psychiatric disorders: a systematic review and meta-analysis. J Clin Psychiatry 82:20r13503. https:\/\/doi.org\/10.4088\/JCP.20r13503","DOI":"10.4088\/JCP.20r13503"},{"key":"6658_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001492","author":"K Kitagawa","year":"2021","unstructured":"Kitagawa K, So R, Nomura N, Tsukahara M et al (2021) Clozapine once-daily versus divided dosing regimen: a cross-sectional study in Japan. J Clin Psychopharmacol. https:\/\/doi.org\/10.1097\/JCP.0000000000001492","journal-title":"J Clin Psychopharmacol"},{"key":"6658_CR13","doi-asserted-by":"publisher","unstructured":"Kuzo N, Haen E, Ho DM, Takeuchi et al (2022) Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci.https:\/\/doi.org\/10.1007\/s00406-022-01542-1","DOI":"10.1007\/s00406-022-01542-1"},{"key":"6658_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/NDT.S39303","volume":"9","author":"G Medic","year":"2013","unstructured":"Medic G, Higashi K, Littlewood KJ, Diez T, Granstr\u00f6m O, Kahn RS (2013) Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 9:119\u2013131. https:\/\/doi.org\/10.2147\/NDT.S39303","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6658_CR15","doi-asserted-by":"publisher","unstructured":"Misdrahi D, Tessier A, Husky M, Lange, A-C Vrijens, B Llorca, P-M Bayl\u00e9, FJ (2018) Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS\u00ae): a six-month post-discharge prospective study. Schizophr Res 193:114\u2013118.https:\/\/doi.org\/10.1016\/j.schres.2017.06.026","DOI":"10.1016\/j.schres.2017.06.026"},{"key":"6658_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","volume":"123","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411\u2013422. https:\/\/doi.org\/10.1111\/j.1600-0447.2011.01710.x","journal-title":"Acta Psychiatr Scand"},{"key":"6658_CR17","unstructured":"Novartis (2015) CLOZARIL\u00ae Product monograph. https:\/\/www.novartis.com\/ca-en\/sites\/novartis_ca\/files\/clozaril_scrip_e.pdf. Accessed 19 Jun 2024"},{"key":"6658_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","volume":"82","author":"RM Procyshyn","year":"2014","unstructured":"Procyshyn RM, Vila-Rodriguez F, Honer WG, Barr AM (2014) Clozapine administered once versus twice daily: does it make a difference? Med Hypotheses 82:225\u2013228. https:\/\/doi.org\/10.1016\/j.mehy.2013.11.043","journal-title":"Med Hypotheses"},{"key":"6658_CR19","doi-asserted-by":"publisher","unstructured":"Sathienluckana T, Jansing T, Srisuriyakamon S, Thonkhunthod A, Sangsuwanto P, Losatiankij P, Supanya S (2023) Comparison of the effectiveness and safety of clozapine between once-daily and divided dosing regimen in patients with treatment-resistant schizophrenia. Ann Pharmacother 10600280231201708. https:\/\/doi.org\/10.1177\/10600280231201708","DOI":"10.1177\/10600280231201708"},{"key":"6658_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/acps.13361","volume":"144","author":"D Siskind","year":"2021","unstructured":"Siskind D, Sharma M, Pawar M, Pearson E, Wagner E, Warren N, Kisely S (2021) Clozapine levels as a predictor for therapeutic response: A systematic review and meta-analysis. Acta Psychiatr Scand 144:422\u2013432. https:\/\/doi.org\/10.1111\/acps.13361","journal-title":"Acta Psychiatr Scand"},{"key":"6658_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1055\/s-0030-1267178","volume":"44","author":"V Stieffenhofer","year":"2011","unstructured":"Stieffenhofer V, Saglam H, Schmidtmann I, Silver H, Hiemke C, Konrad A (2011) Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 44:55\u201359. https:\/\/doi.org\/10.1055\/s-0030-1267178","journal-title":"Pharmacopsychiatry"},{"key":"6658_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/npr2.12118","volume":"40","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Yamazawa R, Suzuki T, Mimura M, Uchida H (2020) Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: a cross-sectional study. Neuropsychopharmacol Rep 40:232\u2013238. https:\/\/doi.org\/10.1002\/npr2.12118","journal-title":"Neuropsychopharmacol Rep"},{"key":"6658_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/acps.12593","volume":"134","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Powell V, Geisler S, DeSanti M, Fervaha G, Agid O, Kane JM, Remington G (2016) Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand 134:234\u2013240. https:\/\/doi.org\/10.1111\/acps.12593","journal-title":"Acta Psychiatr Scand"},{"key":"6658_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001510","author":"X-Y Wang","year":"2022","unstructured":"Wang X-Y, Chan H-Y, Lin C-H (2022) Time to rehospitalization for different oral risperidone dosing frequencies in patients with schizophrenia: a 17-year retrospective cohort study. J Clin Psychopharmacol. https:\/\/doi.org\/10.1097\/JCP.0000000000001510","journal-title":"J Clin Psychopharmacol"},{"key":"6658_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40263-020-00713-9","volume":"34","author":"H Yaegashi","year":"2020","unstructured":"Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H (2020) Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs 34:579\u2013598. https:\/\/doi.org\/10.1007\/s40263-020-00713-9","journal-title":"CNS Drugs"},{"key":"6658_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.10.001","author":"Z Yang","year":"2023","unstructured":"Yang Z, Takeuchi H, Yee JY, See YM, Tang C, Ng BT, Lee J (2023) Once-daily versus divided dosing regimens of clozapine: a cross-sectional study in Singapore. Schizophr Res. https:\/\/doi.org\/10.1016\/j.schres.2023.10.001","journal-title":"Schizophr Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06658-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T17:51:06Z","timestamp":1737222666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6658"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06658-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of the Okayama Psychiatric Medical Center. This board also permitted the inclusion of participants who did not actively reject the use of their data. This study was conducted according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"We analyzed the existing data. Before conducting this study, we provided participants with the opportunity to opt-out if they did not wish to include their data by uploading information about this study on the websites of the Okayama Psychiatric Medical Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"Masaru Tsukahara has received speaker's fees from Eisai and Sumitomo Pharma. Ryuhei So has received research grants from Japan Society for the Promotion of Science, Ministry of Health, Labor and Welfare, Japan Agency for Medical Research and Development, Osake-no-Kagaku Foundation, Mental Health Okamoto Memorial Foundation, and Kobayashi Magobe Memorial Medical Foundation; and speaker's fees from Otsuka, Nippon Shinyaku, and Takeda. Ryuhei So also reports an employment position at CureApp Inc., which develops software as medical devices. Kohei Kitagawa has received a research grant from Japan Society for the Promotion of Science and Policy-based Medical Services Foundation; speaker's fees from Novartis Pharma and Otsuka; manuscript fees from Japanese Society of Psychiatric Pharmacy, Jiho and Nanzando. Yuji Yada has received speaker's fees from Otsuka and Sumitomo Pharma. Masafumi Kodama declared no conflict of interest. Shinichiro Nakajima has received grants from Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Watanabe Foundation, Osakeno-Kagaku Foundation, and Astellas Foundation; and an investigator-initiated clinical study grant from Asahi Quality & Innovations; and research support, manuscript fees, or speaker's fees from Sumitomo Pharma, Meiji Seika Pharma, Otsuka, PDR pharma, and MSD. Yoshiki Kishi has received speaker's fees from Janssen, Otsuka, and Sumitomo Pharma. Norihito Yamada has received grants from Ministry of Health, Labour and Welfare, grants and personal fees from Eisai and Otsuka; and personal fees from Daiichi Sankyo, MSD, UCB, Sumitomo Pharma, and Takeda. Hiroyoshi Takeuchi has received grants from Daiichi Sankyo, Novartis Pharma, and Otsuka; speaker's fees from EA Pharma, Eisai, Kyowa, Janssen, Kyowa,\u00a0Lundbeck, Meiji Seika Pharma,\u00a0Mitsubishi Tanabe Pharma,\u00a0MSD, Otsuka, Sumitomo Pharma, Takeda, and Yoshitomiyakuhin; and consulting fees from\u00a0Boehringer Ingelheim,\u00a0Janssen, Mitsubishi Tanabe Pharma, Ono, and Sumitomo Pharma.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}